Skip to content

Effects of Probiotic Supplementation in Hypertensive Women on Menopause

Effects of Probiotic Supplementation on Autonomic Nervous System Imbalance and Vascular Changes in Hypertensive Menopausal Women: RANDOMIZED CLINICAL TRIAL

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03955159
Enrollment
86
Registered
2019-05-17
Start date
2019-06-10
Completion date
2021-08-10
Last updated
2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Nervous System Imbalance, Dysbiosis, Menopause, Systemic Arterial Hypertension

Brief summary

In postmenopausal women, cardiovascular risk is increased and the mechanisms involving imbalance of the Autonomic Nervous System should be extensively investigated. Recent data suggest a link with intestinal microbiota dysbiosis and probiotic supplementation could be a useful strategy for treating women with increased cardiovascular risk.

Detailed description

After randomization, subjects will be included in their intervention group for a period of three months with initial and final evaluations. The study will evaluate the effects and possible benefits of probiotic supplementation on the functioning of the Autonomic Nervous System and vascular changes in hypertension in menopausal women. The intervention groups will be as follows: 1. \- Menopausal women with hypertension + Probiotic supplementation 2. \- Menopausal women with hypertension + Placebo supplementation

Interventions

DIETARY_SUPPLEMENTProbiotic supplementation

The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.

Sponsors

Instituto de Cardiologia do Rio Grande do Sul
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Hypertensive * At least 1 year of menopause * Sedentary

Exclusion criteria

* Smoker * Use of psychiatric medications * Cardiovascular events * Recent surgeries * Diabetic * Use of beta blockers

Design outcomes

Primary

MeasureTime frameDescription
Autonomic Nervous System3 monthsThe data will be collected through the system of acquisition of pressure waves in a continuous and non-invasive way by the Finometer® system, through a cuffing installed in the middle finger, taking this signal to an analog-to-digital signal converter. The pulse pressure signal will be acquired at 1000 Hz, continuously and non-invasively, supine (10 minutes) in a quiet environment, with controlled temperature (± 23 ° C) and illumination. The collected data will be saved in the software BeatsScope® and LabChart®, from which will be extracted the syistograms for analysis. The autonomic nervous system will be assessed at baseline and after 3 months of intervention.

Countries

Brazil

Contacts

Primary ContactAline Dalmazo, Especialist
aline@dalmazo.com+5551999774646
Backup ContactMaria Claudia Irigoyen, PhD
hipirigoyen@gmail.com+555132303600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026